Amphotericin B intralipid formulation: Stability and particle size

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue 6, 1996, Pages 1165-1169

  Ranchere J Y ^a   Latour, J F ^a   Fuhrmann, C ^a   Lagallarde, C ^b   Loreuil, F ^c  

^a CENTRE LÉON BÉRARD   (France)

^b Kabi Pharmacia ^*  (Sweden)

^c Laboratories Bruneau   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; INTRALIPID;

ARTICLE; DRUG STABILITY; DRUG TOXICITY; MYCOSIS; PARTICLE SIZE; PRECIPITATION;

AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTIFUNGAL; DRUG STABILITY; FAT EMULSIONS, INTRAVENOUS; OSMOLAR CONCENTRATION; PRECIPITATION; SYRINGES; TIME FACTORS;

EID: 0029779945     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.6.1165     Document Type: Article

References (10)

1. Bodey, G., Bueltmann, B., Duguid, W., Gibbs, D., Hanack, H., Hotchi, M. et al. (1992). Fungal infections in cancer patients: an international autopsy survey. European Journal of Clinical Microbiology and Infectious Diseases 11, 99-109.
2. Caillot, D., Reny, G., Solary, E., Casasnovas, O., Chavanet, P., Bonnette, B. et al. (1994). A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. Journal of Antimicrobial Chemotherapy 33, 603-13.
3. Kintzel, P. E. & Smith, G. H. (1992). Practical guidelines for preparing and administering amphotericin B. American Journal of Hospital Pharmacists 49, 1156-64.
4. Kirsh, R., Goldstein, R., Tarloff, J., Parris, D., Hook, J., Hanna, N. et al. (1988). An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. Journal of Infectious Diseases 158, 1065-70.
5. Mills, W., Chopra, R., Linch, D. C. & Golstone, A. H. (1994). Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-center experience of 133 episodes in 116 patients. British Journal of Hematology 86, 754-60.
6. Moreau, P., Milpied, N., Fayette, N., Ramée, J. F. & Harousseau, J. L. (1992). Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutropenic patients. Journal of Antimicrobial Chemotherapy 30, 535-41.
7. Perfect, J. R., Pickard, W. W., Hunt, D. L., Palmer, B. & Schell, W. A. (1991). The use of amphotericin B in nosocomial fungal infection. Reviews of Infectious Diseases 13, 474-9.
8. Persson, U., Tennval, G. R., Anderson, S., Tyden, G. & Wettermak, B. (1992). Cost effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. Pharmacoeconomics 2, 500-8.
9. Warnock, D. (1991). Amphotericin B: an introduction. Journal of Antimicrobial Chemotherapy 28, Suppl. B, 27-38.
10. Washington, C., Lance, M. & Davis, S. S. (1993). Toxicity of amphotericin B emulsion formulation. Journal of Antimicrobial Chemotherapy 31, 806-8.